Drug Trial Radar · NCT04821687
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
Last checked: Nov 19, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Jun 17, 2021
Primary completion
Aug 18, 2022
Study completion Aug 18, 2022
Sponsor
- Lead sponsor
- SK Chemicals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.
Conditions
- Parkinson Disease
Interventions
Ongentys 50mgDrug
Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
Madopar Tab. 125 or Perkin Tab. 25-100mgDrug
Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hauser's diaryTime frame: Baseline, at 2 weeks, and 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hallym University Sacred Heart Hospital
Anyang-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.